Gene-based therapies for neuromuscular disorders

Area of Science:

• * Genetics and Molecular Biology
• * Neurology
• * Medical Therapeutics

Background:

• * Neuromuscular diseases (NMD) encompass diverse acquired and genetic conditions.
• * Significant progress in treating genetic NMD has been driven by gene regulation therapies.
• * Gene replacement, small interfering RNA (siRNA), and antisense antinucleotides represent key therapeutic strategies.

Purpose of the Study:

• * To review recent advancements in gene-based therapies for neuromuscular diseases.
• * To highlight the application of gene regulation strategies in treating genetic NMD.
• * To focus on motor neuron diseases, neuropathies, and Duchenne muscular dystrophy.

Main Methods:

• * Literature review of recent developments in gene-based therapies for NMD.
• * Analysis of gene replacement, siRNA, and antisense antinucleotide approaches.
• * Examination of therapeutic progress in specific NMD subtypes.

Main Results:

• * Gene-based therapies, particularly gene replacement, siRNA, and antisense antinucleotides, show significant promise.
• * Several gene therapies for genetic NMD have achieved regulatory approval or are in late-stage development.
• * These advancements offer new hope for patients with motor neuron diseases, neuropathies, and Duchenne muscular dystrophy.

Conclusions:

• * Gene regulation therapies are transforming the treatment landscape for genetic neuromuscular diseases.
• * The development and approval of novel gene-based treatments are rapidly advancing.
• * Continued research and clinical application of these therapies are crucial for managing NMD.